Sign up USA
Proactive Investors - Run By Investors For Investors

Oragenics is well funded to resume Phase 2 clinical trial for oral mucositis

Oragenics Inc (NYSEAMERICAN:OGEN) CEO Alan Joslyn updates Proactive Investors on the Florida based biotech's advancements in the last six months.

Joslyn says the company's lead candidate AG013, which treats oral mucositis, resumed its Phase 2 clinical trial of AG013, following a positive review by an independent Data Safety Monitoring Board, with data expected in the middle of 2019. Joslyn says the trial will soon be expanded into 50 centers in the US and into Europe to complete patient enrollment.

Joslyn says the company recently raised $13.8mln to carry the biotech's programs through clinical trials. He says from this point forward most of the work within the company is operational.

 
Meet Arix Bioscience Plc, Avacta Group Plc and Silence Therapeutics plc at our event, London , 04 October 2018. Register here »
View full OGEN profile View Profile

Oragenics Inc Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use